Researchers at Baylor College of Medicine have unveiled a previously unrecognized pathway through which metformin exerts its anti-diabetic effects, highlighting the drug’s action in the brain. This discovery, published in Science Advances, identifies the Rap1 protein in the ventromedial hypothalamus as a critical player in metformin’s ability to lower blood sugar. By suppressing Rap1 activity, metformin activates specific neurons that regulate glucose metabolism, a finding that shifts the understanding of how this longstanding diabetes treatment operates.

This breakthrough is significant for the longevity and healthspan field as it opens avenues for developing more targeted diabetes therapies that leverage brain pathways. The study suggests that metformin’s effectiveness may not solely depend on its actions in the liver or gut, but also relies on its capacity to influence brain function at much lower doses. This could lead to novel treatments that directly engage the brain’s metabolic centers, potentially enhancing both diabetes management and cognitive health.

One key takeaway from this research is the potential for metformin to be repurposed or modified to target brain-specific mechanisms, which could not only improve diabetes outcomes but also further elucidate its effects on brain aging and overall healthspan.

Source: sciencedaily.com